ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 114

Incidence of Inflammatory Arthritis Before and After Inflammatory Bowel Disease Diagnosis: A Population-Based Cohort Study

Roberta A Berard1, Ellen Kuenzig2, Jessica Widdifield3, Eric Benchimol4, Melody Lam5, Vipul Jairath6, Sherry Rohekar7, Laura Targownik4, Melanie Watson8 and Eileen Crowley9, 1London Health Sciences Centre, London, ON, Canada, 2Schulich- University of Western Ontario, ON, Canada, 3Sunnybrook Research Institute, Toronto, ON, Canada, 4University of Toronto, ON, Canada, 5ICES, ON, Canada, 6Western University, London, ON, Canada, 7University of Western Ontario - London, London, ON, Canada, 8Western University, ON, Canada, 9London Children's Hospital, ON, Canada

Meeting: 2026 Pediatric Rheumatology Symposium

Session Information

Date: Friday, March 20, 2026

Title: Abstracts: Pediatric Rheumatology Potpourri

Session Time: 4:43PM-4:48PM

Background/Purpose: Arthropathies are a common extra-intestinal manifestation of IBD, yet population-level data on the risk of inflammatory arthritis (IA) among individuals newly diagnosed with inflammatory bowel disease (IBD) is lacking. Describe the incidence of IA among incident IBD cases.

Methods: We used population-based health administrative data from Ontario, Canada to identify all incident IBD cases diagnosed between April 1, 2003 and March 31, 2020 using previously validated age-specific algorithms. Among individuals in this inception cohort of IBD patients, we identified individuals diagnosed with IA either before or after their IBD diagnosis. IA diagnosis (rheumatoid arthritis, axial spondylitis, other seronegative spondyloarthropathies, synovitis) required ≥1 hospitalization or emergency department visit or ≥2 physician claims with an IA diagnosis code, with ≥1 claim made by a rheumatologist (adult or pediatric), internal medicine physician, pediatrician, or gastroenterologist. IA diagnoses could occur at any point during data availability (1991-2024). We calculated the time between the diagnoses of IA and IBD, categorizing time into the intervals (>3 years pre-IBD diagnosis to >10-15 years post-IBD diagnosis). Age- and sex-standardized IA incidence rates were calculated within each interval. Analyses were stratified by IBD type, age at IBD diagnosis (< 18y, 18 to 64y, ≥65y), and sex.

Results: We identified 56,776 individuals with incident IBD; 11,814 (20.8%) had an IA diagnosis. The incidence of IA peaked in the 6 months prior to IBD diagnosis (23.1 (95% CI 18.6 to 28.4) per 1000 person-years), then gradually decreased in the time following IBD diagnosis (Figure). This pattern was consistent in all subgroups.

Conclusion: This is the first population-based study to describe the incidence of IA in an inception cohort of people with IBD. The peak in IA diagnosis around the time of IBD diagnosis indicates a need for integrated interprofessional care models to facilitate patient access to both gastroenterology and rheumatology care. Future research will investigate the implications of these co-occurring diagnoses on health services utilization and expenditures.

Figure. Incidence of IA among incident IBD cases, stratified by sexSupporting image 1

Disclosures: R. Berard: AbbVie/Abbott, 1, Celltrion, 12, advisory board; E. Kuenzig: None; J. Widdifield: None; E. Benchimol: None; M. Lam: None; V. Jairath: AbbVie, 2, 6, Amgen, 2, Anaptys Bio, 2, Asahi Kasei, 2, Asieris, 2, AstraZeneca, 2, Attovia, 2, Biomebank, 2, Biosciences, 2, Blackbird Labs, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Caldera, 2, Calluna, 2, Catalytic Health, 2, Celltrion, 2, Eli Lilly, 2, Ensho, 2, Enthera, 2, Exeliome, 2, Ferring, 2, Fresenius Kabi, 2, Gilead, 2, GlaxoSmithKlein(GSK), 2, Granite Bio, 2, Janssen, 2, Merck/MSD, 2, Mountainfield, 2, MRM Health, 2, Nxera, 2, Organon, 2, OSE Immounotherapeautics, 2, OSE Immunotherapeutics, 2, Pendopharm, 2, 2, Pfizer, 2, Pioneering Medicine, 2, Prometheus, 2, Roche/Genentech, 2, Sandofi, 2, SCOPE, 2, Shattuck Labs, 2, Sorriso, 2, Spyre, 2, Synedgen, 2, Takeda, 2, Teva, 2, Tillotts, 2, Union Therapeutics, 2, Ventus, 2, Ventyx, 2, Vividion, 2, Xencor, 2, Zealand Pharma, 2; S. Rohekar: AbbVie/Abbott, 1, 6, Celltrion, 1, 6, Eli Lilly, 1, 6, Fresenius Kabi, 1, 6, Janssen, 1, 6, Novartis, 1, 6, Pfizer, 1, 6, Roche, 1, 6, Sun, 6, UCB, 1, 5, 6, Viatris, 1, 6; L. Targownik: Amgen, 2, Eli Lilly, 2, Janssen, 2, 5, 6, Merck/MSD, 2, Pfizer, 1, 2, 6; M. Watson: AbbVie/Abbott, 2, Amgen, 6, Pfizer, 2; E. Crowley: Abbvie, 5, Alimentiv Inc., 2, Pfizer, 5, Sanofi, 2.

To cite this abstract in AMA style:

Berard R, Kuenzig E, Widdifield J, Benchimol E, Lam M, Jairath V, Rohekar S, Targownik L, Watson M, Crowley E. Incidence of Inflammatory Arthritis Before and After Inflammatory Bowel Disease Diagnosis: A Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/incidence-of-inflammatory-arthritis-before-and-after-inflammatory-bowel-disease-diagnosis-a-population-based-cohort-study/. Accessed .

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-inflammatory-arthritis-before-and-after-inflammatory-bowel-disease-diagnosis-a-population-based-cohort-study/